Goldstream Capital Management Ltd Lowers Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Goldstream Capital Management Ltd trimmed its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 77.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 500 shares of the exchange traded fund’s stock after selling 1,700 shares during the period. SPDR S&P Biotech ETF makes up approximately 0.0% of Goldstream Capital Management Ltd’s portfolio, making the stock its 21st largest holding. Goldstream Capital Management Ltd’s holdings in SPDR S&P Biotech ETF were worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. James J. Burns & Company LLC grew its position in SPDR S&P Biotech ETF by 5.0% in the 3rd quarter. James J. Burns & Company LLC now owns 3,062 shares of the exchange traded fund’s stock valued at $224,000 after buying an additional 146 shares during the last quarter. Greenwich Wealth Management LLC boosted its position in shares of SPDR S&P Biotech ETF by 1.4% during the 4th quarter. Greenwich Wealth Management LLC now owns 11,451 shares of the exchange traded fund’s stock worth $1,022,000 after purchasing an additional 155 shares in the last quarter. Moser Wealth Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 10.4% during the 3rd quarter. Moser Wealth Advisors LLC now owns 2,041 shares of the exchange traded fund’s stock worth $149,000 after purchasing an additional 193 shares in the last quarter. Viewpoint Capital Management LLC boosted its position in shares of SPDR S&P Biotech ETF by 25.0% during the 3rd quarter. Viewpoint Capital Management LLC now owns 1,000 shares of the exchange traded fund’s stock worth $73,000 after purchasing an additional 200 shares in the last quarter. Finally, HB Wealth Management LLC boosted its position in shares of SPDR S&P Biotech ETF by 4.9% during the 4th quarter. HB Wealth Management LLC now owns 4,280 shares of the exchange traded fund’s stock worth $382,000 after purchasing an additional 200 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA XBI traded up $1.01 during trading on Thursday, hitting $88.34. 10,196,406 shares of the company were exchanged, compared to its average volume of 11,705,903. The company has a market cap of $6.73 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1 year low of $63.80 and a 1 year high of $103.52. The firm’s fifty day moving average price is $92.28 and its 200 day moving average price is $85.06.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.